PRO-HEBNCT05424016
Propranolol and Von Hippel-Lindau Disease
StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 2 with changes below, 1 re-verified with no change.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Dec 2023); last known: Recruiting
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Sep 1, 2022 to Jan 16, 2023
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
total and individual hemangioblastomas' volume measured by MRI
Timeframe: 24 months
Secondary (7)
To compare the safety (tolerance) between the two treatment arms at 24 months post-randomization
To Compare the growth rate of HB between the two treatment arms at 24 months post-randomization
Compare the extent of peritumoral edema between the two treatment arms
Compare the development of de novo lesions between the two treatment arms every 6 months
Compare the angiogenic profile of BHs between the two groups every 6 months
Show 2 moreShow less
Study the evolution of serum VEGF level under treatment at 12 and 24 months
Compare the number of patients requiring surgery between the two treatment arms
Arms and interventions
Experimental armExperimental
Patients with no contraindications will be included and randomized to receive propranolol orally for 24 months
control armOther
Patient included with a routine follow-up
Drugs: Propranolol
Other: follow-up
Sites
1 site in 1 country
- AP-HP, Bicêtre HospitalLe Kremlin-Bicêtre, France